Replies to post #211201 on Biotech Values

[JohnWayne]

MRK: between this and the Tecentriq bladder failure, today was a good day for Keytruda.

OT: not sure I've ever seen "irrespective" used in a biotech press release headline before! At least it wasn't "irregardless" ;)

[semi_infinite]

Seems that BMY's IV dropped most on Roche news and further dropped this morning before MRK's news. IV's dropped >50% since 2 days ago for this week's options and dropped 1/3 for further expiries. Hindsight suggests tecentriq was the reason for nervousness re BMY.